Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer - Contacts and Locations

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.

Study NCT00072631. Last updated on October 2, 2008. Information provided by OSI Pharmaceuticals

Please refer to this study by its ClinicalTrials.gov identifier: NCT00072631

Locations


United States, Texas
	Institute for Drug DevelopmentCancer Therapy and Research Center
	San Antonio, Texas, United States, 78229

Sponsors and Collaborators

OSI Pharmaceuticals